Redeye initiates coverage of 2cureX
2020-08-31 07:55:00
Redeye initiates coverage of 2cureX, a diagnostics company set to commercialize its precision test for colorectal cancer drugs. IndiTreat’s enabling of targeted individual treatment, with potential positive clinical trial results in Q1 2021, lays the ground for substantial future sales. Although the share has soared lately, the case still offers additional upside in the short to medium term.
Read more and download the Research Report
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/